CERS Stock Risk & Deep Value Analysis
Cerus Corp
Healthcare • Medical Devices
DVR Score
out of 10
What You Need to Know About CERS Stock
We analyzed Cerus Corp using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CERS through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is CERS Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
High
Regulatory Risk
High
What Are the Red Flags for CERS?
- ⚠
Further delays in RBC system clinical trials or regulatory approval process
- ⚠
Higher-than-expected cash burn leading to significant, dilutive capital raises
- ⚠
Negative outcomes from ongoing clinical studies for RBC or other pipeline products
Unlock CERS Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Cerus Corp (CERS) Do?
Market Cap
$309.59M
Sector
Healthcare
Industry
Medical Devices
Employees
614
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
Visit Cerus Corp WebsiteIs CERS Stock Undervalued?
Unlock the full AI analysis for CERS
Get the complete DVR score, risk analysis, and more
Does CERS Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The INTERCEPT system benefits from regulatory approvals and established clinical data, creating high switching costs for blood centers. The RBC system, if approved, would create a new, durable moat through a new standard of care and extensive IP, making it difficult for competitors to replicate.
Moat Erosion Risks
- •Failure to secure timely regulatory approval for the RBC system in key markets.
- •Emergence of superior or cheaper alternative pathogen reduction technologies.
- •Changes in blood safety guidelines or regulatory landscape that reduce the need for pathogen reduction.
CERS Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive CERS Stock Higher?
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Expected mid-March 2026)
- •Updates on S&T (Safety & Efficacy Trial) progress for RBC system (Q2-Q3 2026)
Medium-Term (6-18 months)
- •Potential submission of a BLA (Biologics License Application) for RBC system (Late 2026 / Early 2027)
- •Expansion of INTERCEPT Blood System sales into new international markets
Long-Term (18+ months)
- •FDA approval and initial commercial launch of the RBC pathogen reduction system (2028+)
- •Broad adoption of RBC system disrupting traditional blood safety market
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for CERS?
- ✓
Positive clinical trial data and regulatory progress for the RBC system.
- ✓
Decreasing cash burn rate or path to profitability becoming clearer.
- ✓
Significant adoption rates of INTERCEPT in new geographies.
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for CERS (Cerus Corp) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
